DESIGN AND OPTIMIZATION OF NANO ENCAPSULATED BERBERIS ASIATICA BIO COMPOUNDS
DOI:
https://doi.org/10.22159/ijap.2023v15i6.48800Keywords:
Berberis asiatica, Nanoparticles, Box-behnken desin, Chitosan, Entrapment efficiencyAbstract
Objective: The current study goal is to develop and optimize nanoencapsulated biocompounds of Berberis asiatica (BCBA) utilizing the ionic gelation process to target the kidney for antiurolithiatic activity.
Methods: Nanoencapsulated BCBA was prepared employing the ionic gelation method. Box Behnken Design (BBD) 3-factor, 3-level is used to examine the effects of formulation parameters and to enhance the desired responses. Characterization studies include Fourier transform infrared (FTIR), X-ray diffraction (XRD), particle size, zeta potential, scanning electron microscopy (SEM), and transmission electron microscopy (TEM) performed to study the quality of optimized nanoparticles.
Results: Mathematical equations and response surface plots were used to relate the dependent and independent variables. Diagnostic charts were used to show the varied factor level permutations. The percentages of entrapment efficiency (% EE) and drug release (% DR) used in evaluation studies of optimized biocompounds of Berberis asiatica nanoparticles (OBCBANPs) were determined to be 83.7% and 78.33%, respectively. The Fourier transform infrared (FTIR) results showed that chitosan, sodium tripolyphosphate (NaTPP), and BACB were compatible. Due to chitosan and NaTPP gelation in the case of OBCBANPs, X-ray diffraction (XRD) analyses have acknowledged the crystalinity. The particle size and zeta potential of the optimized formulation, found to be 95.4 nm and 31 mV, respectively, indicate the nanoparticles are in the nano range and possess extreme stability by preventing particle convergence. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) studies reveal that the optimized formulation nanoparticles are spherical in shape, homogeneous, and have little aggregation. The accelerated stability studies showed that the optimized formulation was stable at different temperatures and relative humidity.
Conclusion: The stable optimized formulation was prepared, evaluated, and characterized. BBD is employed to optimize the formulation by minimizing the number of experimental runs and enhancing the desired responses. The optimized formulation further needs to investigate the invivo studies for antiurolithiatic activity by targeting the kidney.
Downloads
References
Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18. doi: 10.1016/j.colsurfb.2009.09.001, PMID 19782542.
Tønnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002;28(6):621-30. doi: 10.1081/ddc-120003853, PMID 12149954.
Asgharian S, Lorigooini Z, Rafieian R, Rafieian Kopaei M, Kheiri S, Nasri H. The preventive effect of Berberis vulgaris extract on contrast-induced acute kidney injury. J Nephropathol. 2017;6(4):395-8. doi: 10.15171/jnp.2017.65.
Balaji LG, Banji D, Banji JF. Evaluation of antiurolithiatic activity of the aqueous and alcoholic extracts of roots of boerhaavia diffusa. Indo Am J Pharm Res. 2015;5(1):525-30. doi: 10.1044/1980-iajpr.150115.
Geng X, Zhang M, Lai X, Tan L, Liu J, Yu M. Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment. Adv Healthc Mater. 2018;7(21):e1800558. doi: 10.1002/adhm.201800558, PMID 30277665.
Wang J, Masehi Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci. 2017;5(8):1450-9. doi: 10.1039/c7bm00271h, PMID 28516997.
Gao S, Hein S, Dagnæs Hansen F, Weyer K, Yang C, Nielsen R. Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing. Theranostics. 2014;4(10):1039-51. doi: 10.7150/thno.7866, PMID 25157280.
Qiao H, Sun M, Su Z, Xie Y, Chen M, Zong L. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan. Biomaterials. 2014;35(25):7157-71. doi: 10.1016/j.biomaterials.2014.04.106.
El-ASSAL MI, Samuel D. Optimization of rivastigmine chitosan nanoparticles for neurodegenerative alzheimer; in vitro and ex vivo characterizations. Int J Pharm Pharm Sci. 2022;14(1):17-27. doi: 10.22159/ijpps.2022v14i1.43145.
Yuan ZX, Zhang ZR, Zhu D, Sun X, Gong T, Liu J. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm. 2009;6(1):305-14. doi: 10.1021/mp800078a, PMID 19035784.
Patel M, Patel NV, Patel TB. Design and development of rilpivirine nanoparticle containing chitosan using ionic gelation method for hiv infections. Int J Pharm Pharm Sci. 2020;12(2):113-8. doi: 10.22159/ijpps.2020v12i2.35814.
Vozza G, Danish M, Byrne HJ, Frias JM, Ryan SM. Application of box-behnken experimental design for the formulation and optimisation of selenomethionine-loaded chitosan nanoparticles coated with zein for oral delivery. Int J Pharm. 2018;551(1-2):257-69. doi: 10.1016/j.ijpharm.2018.08.050, PMID 30153488.
Ghose D, Patra CN, Swain S, Sruti J. Box-Behnken design-based development and characterization of polymeric freeze-dried nanoparticles of isradipine for improved oral bioavailability. Int J App Pharm. 2023;15(4):60-70. doi: 10.22159/ijap.2023v15i4.47728.
Mao CF, Zhang XR, Johnson A, He JL, Kong ZL. Modulation of diabetes mellitus-induced male rat reproductive dysfunction with micro-nanoencapsulated echinacea purpurea ethanol extract. BioMed Res Int. 2018;2018:4237354. doi: 10.1155/2018/4237354, PMID 30246020.
Abo-Elseoud WS, Hassan ML, Sabaa MW, Basha M, Hassan EA, Fadel SM. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide. Int J Biol Macromol. 2018;111:604-13. doi: 10.1016/j.ijbiomac.2018.01.044, PMID 29325745.
Padmaa PM, Preethy AJ, Setty CM, Peter GCV. Release kinetics–concepts and applications. IJPRT. 2018;8(1):12-20.
Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010;7(4):429-44. doi: 10.1517/17425241003602259, PMID 20331353.
Ruhi R, Sarika W, Vinay S, Ram G. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;1(109):27-35. doi: 10.1016/j. ijbiomac.2017.12.056.
Sonali BS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients, a comprehensive review. J Excipients Food Chem. 2010;1(3):3-25.
Sharma R, Yasir M, Bhaskar S, Asif M. Formulation and evaluation of paclitaxel loaded PSA-PEG nanoparticles. J Appl Pharm Sci. 2011;1(5):96-8.
Gannu R, Palem CR, Yamsani SK, Yamsani VV, Yamsani MR. Enhanced bioavailability of buspirone from reservoir-based transdermal therapeutic system, optimization of formulation employing box–behnken statistical design. AAPS PharmSciTech. 2010;11(2):976-85. doi: 10.1208/s12249-010-9451-7, PMID 20517714.
Abul Kalam M, Khan AA, Khan S, Almalik A, Alshamsan A. Optimizing indomethacin-loaded chitosan nanoparticle size, encapsulation, and release using Box-Behnken experimental design. Int J Biol Macromol. 2016;87:329-40. doi: 10.1016/j.ijbiomac.2016.02.033, PMID 26893052.
Meng J, Sturgis TF, Youan BB. Engineering tenofovir-loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci. 2011;44(1-2):57-67. doi: 10.1016/j.ejps.2011.06.007, PMID 21704704.
Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-Behnken design. AAPS PharmSciTech. 2007;8(4):E86. doi: 10.1208/pt0804086, PMID 18181547.
Gannu R, Palem CR, Yamsani SK, Yamsani VV, Yamsani MR. Enhanced bioavailability of buspirone from the reservoir-based transdermal therapeutic system, optimization of formulation employing box–behnken statistical design. AAPS PharmSciTech. 2010;11(2):976-85. doi: 10.1208/s12249-010-9451-7, PMID 20517714.
Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo antiparkinson activity. Int J Biol Macromol. 2018;109:27-35. doi: 10.1016/j.ijbiomac.2017.12.056, PMID 29247729.
Rukmangathen R, Yallamalli IM, Yalavarthi PR. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. Drug Dev Ind Pharm. 2019;45(8):1342-50. doi: 10.1080/03639045.2019.1619759, PMID 31094571.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Kishore Bandarapalle
This work is licensed under a Creative Commons Attribution 4.0 International License.
